Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toll‐like receptor ligands as adjuvants in allergen‐specific immunotherapy
Pål Johansen, Gabriela Senti, Julia M. Martínez Gómez, et al.
Clinical & Experimental Allergy (2005) Vol. 35, Iss. 12, pp. 1591-1598
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections
Gabriela Senti, Reto Crameri, Daniela Kuster, et al.
Journal of Allergy and Clinical Immunology (2012) Vol. 129, Iss. 5, pp. 1290-1296
Open Access | Times Cited: 260
Antigen kinetics determines immune reactivity
Pål Johansen, Tazio Storni, Lorna Rettig, et al.
Proceedings of the National Academy of Sciences (2008) Vol. 105, Iss. 13, pp. 5189-5194
Open Access | Times Cited: 173
Toll-Like Receptors and Leishmaniasis
Felipe Francisco Tuon, Valdir Sabbaga Amato, Hélio Arthur Bacha, et al.
Infection and Immunity (2007) Vol. 76, Iss. 3, pp. 866-872
Open Access | Times Cited: 135
Intralymphatic Injections as a New Administration Route for Allergen-Specific Immunotherapy
Julia M. Martínez-Gómez, Pål Johansen, Iris Erdmann, et al.
International Archives of Allergy and Immunology (2009) Vol. 150, Iss. 1, pp. 59-65
Open Access | Times Cited: 112
A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice
Young Mee Yoon, Jamal S. Lewis, Matthew R. Carstens, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 77
Mouse Models for Food Allergies: Where Do We Stand?
Stefan Schülke, Melanie Albrecht
Cells (2019) Vol. 8, Iss. 6, pp. 546-546
Open Access | Times Cited: 54
Bee Venom—A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
Keneth Iceland Kasozi, Gniewko Niedbała, Mohammed Alqarni, et al.
Frontiers in Public Health (2020) Vol. 8
Open Access | Times Cited: 53
Toll-like receptor (TLR) 2–9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses
Tarun Kanti Ghosh, Dan J. Mickelson, Jason R Fink, et al.
Cellular Immunology (2006) Vol. 243, Iss. 1, pp. 48-57
Closed Access | Times Cited: 108
Intralymphatic immunotherapy
Gabriela Senti, Pål Johansen, Thomas M. Kündig
Current Opinion in Allergy and Clinical Immunology (2009) Vol. 9, Iss. 6, pp. 537-543
Closed Access | Times Cited: 81
Resiquimod and other immune response modifiers as vaccine adjuvants
Mark A. Tomai, Richard L. Miller, Kenneth E. Lipson, et al.
Expert Review of Vaccines (2007) Vol. 6, Iss. 5, pp. 835-847
Closed Access | Times Cited: 80
Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response
Stefan Fischer, Eva Schlosser, Marc Mueller, et al.
Journal of drug targeting (2009) Vol. 17, Iss. 8, pp. 652-661
Closed Access | Times Cited: 75
New Directions in Immunotherapy
Linda Cox, Enrico Compalati, Thomas M. Kündig, et al.
Current Allergy and Asthma Reports (2013) Vol. 13, Iss. 2, pp. 178-195
Open Access | Times Cited: 63
Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling
Deborah Leuthard, Agathe Duda, Sandra N. Freiberger, et al.
The Journal of Immunology (2018) Vol. 200, Iss. 9, pp. 3151-3159
Open Access | Times Cited: 48
A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles
Julia M. Martínez Gómez, Stefan Fischer, Noémi Csaba, et al.
Pharmaceutical Research (2007) Vol. 24, Iss. 10, pp. 1927-1935
Open Access | Times Cited: 63
Agonists of Toll-Like Receptors 3, 4, 7, and 9 Are Candidates for Use as Adjuvants in an Outer Membrane Vaccine againstNeisseria meningitidisSerogroup B
Floris Fransen, Claire J. P. Boog, Jos P. M. van Putten, et al.
Infection and Immunity (2007) Vol. 75, Iss. 12, pp. 5939-5946
Open Access | Times Cited: 63
A fusion protein of flagellin and ovalbumin suppresses the TH2 response and prevents murine intestinal allergy
Stefan Schülke, Manja Burggraf, Zoe Waibler, et al.
Journal of Allergy and Clinical Immunology (2011) Vol. 128, Iss. 6, pp. 1340-1348.e12
Open Access | Times Cited: 60
Adjuvants for allergy vaccines
Philippe Moingeon
Human Vaccines & Immunotherapeutics (2012) Vol. 8, Iss. 10, pp. 1492-1498
Open Access | Times Cited: 57
IL‐4 receptor α blockade prevents sensitization and alters acute and long‐lasting effects of allergen‐specific immunotherapy of murine allergic asthma
Dennis Rußkamp, Juan Antonio Aguilar‐Pimentel, Francesca Alessandrini, et al.
Allergy (2019) Vol. 74, Iss. 8, pp. 1549-1560
Open Access | Times Cited: 42
Novel vaccines and adjuvants for allergen-specific immunotherapy
Reto Crameri, Claudio Rhyner
Current Opinion in Immunology (2006) Vol. 18, Iss. 6, pp. 761-768
Closed Access | Times Cited: 57
Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy
Julia M. Martínez-Gómez, Pål Johansen, Horst Rose, et al.
Allergy (2008) Vol. 64, Iss. 1, pp. 172-178
Closed Access | Times Cited: 51
Overview and Outlook of Toll-like Receptor ligand–antigen Conjugate Vaccines
Yoshio Fujita, Hiroaki Taguchi
Therapeutic Delivery (2012) Vol. 3, Iss. 6, pp. 749-760
Closed Access | Times Cited: 46
Novel Delivery Routes for Allergy Immunotherapy
Gabriela Senti, Thomas M. Kündig
Immunology and Allergy Clinics of North America (2015) Vol. 36, Iss. 1, pp. 25-37
Closed Access | Times Cited: 38
mRNA vaccination as a safe approach for specific protection from type I allergy
Richard Weiss, Sandra Scheiblhofer, Elisabeth Roesler, et al.
Expert Review of Vaccines (2011) Vol. 11, Iss. 1, pp. 55-67
Closed Access | Times Cited: 39
New routes for allergen immunotherapy
Pål Johansen, Seraina von Moos, Deepa Mohanan, et al.
Human Vaccines & Immunotherapeutics (2012) Vol. 8, Iss. 10, pp. 1525-1533
Open Access | Times Cited: 36
Adjuvants and Vector Systems for Allergy Vaccines
Philippe Moingeon, Vincent Lombardi, Nathalie Saint-Lu, et al.
Immunology and Allergy Clinics of North America (2011) Vol. 31, Iss. 2, pp. 407-419
Closed Access | Times Cited: 35
Page 1 - Next Page

Scroll to top